OptiPharm Co Ltd

OptiPharm's capital structure shows a debt-to-equity ratio of 0.42, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1.21, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's operating cash flow is negative at -1.55 billion KRW, and its free cash flow is also negative at -3.37 billion KRW, indicating cash flow challenges. In terms of profitability, OptiPharm reported a net loss of 2.5 billion KRW and an operating loss of 2.41 billion KRW. The company's return on equity is -9.84%, and its return on assets is -6.13%, both significantly below the industry norms for pharmaceutical companies. The gross profit margin is 25.0%, which is in line with the industry average, but the operating margin is negative, reflecting operational inefficiencies. OptiPharm's revenue is distributed across two segments: Sale Business and New Business. The Sale Business segment is involved in livestock disease appraisal services, animal drug distribution, and feed additive manufacturing, while the New Business segment focuses on R&D of heterologous organisms, VLP vaccines, and human diagnostic kits. The company's geographic exposure is primarily domestic, with some overseas markets, but the input data does not provide specific revenue concentration figures. The company's growth trajectory is uncertain, as it reported a net loss and negative operating income. The outlook for the current fiscal year does not provide specific numeric deltas, but the negative financial performance suggests a challenging growth environment. The company's capital expenditure of -2.54 billion KRW indicates investment in long-term assets, but the negative free cash flow suggests that these investments are not yet generating positive returns. Risk factors for OptiPharm include liquidity concerns, as the company has a medium liquidity risk rating. The company's net cash is negative after subtracting total debt, which could limit its ability to fund operations and investments. The dilution risk is low, but the company's negative free cash flow and operating cash flow could lead to future dilution if not addressed. The risk assessment also notes that the company's liquidity position is a key flag. Recent events and filings for OptiPharm are not detailed in the input data, but the company's financial performance and risk factors suggest that it may need to address its liquidity and profitability issues. The company's focus on R&D in new business areas could be a long-term growth driver, but the current financial challenges may hinder its ability to capitalize on these opportunities.